[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346187-105":59,"doc-detail-346187-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genetic-alterations-and-targeted-therapies-in-salivary-gland-neoplasms","Genetic alterations and targeted therapies in salivary gland neoplasms","","Salivary gland neoplasms (SGNs) comprise diverse benign and malignant tumors driven by distinct genetic abnormalities that shape pathogenesis and clinical behavior. This review integrates evidence on molecular alterations underlying SGNs and emphasizes emerging, translational therapeutic targets. Searches across PubMed, Google Scholar, Cochrane, and SCOPUS cover studies from 1990–2025, focusing on genetic aberrations, oncogenic fusions, and targeted regimens. Findings suggest that small-molecule inhibitors and other targeted agents could complement or improve on conventional chemotherapy, while data limitations and the need for clinical validation remain significant.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genetic-alterations-and-targeted-therapies-in-salivary-gland-neoplasms/346187/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genetic-alterations-and-targeted-therapies-in-salivary-gland-neoplasms/346187.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the review focus on regarding salivary gland neoplasms?","Question",{"text":112,"@type":113},"It focuses on genetic and molecular alterations in SGNs and how they relate to diagnosis, prognosis, and targeted therapy development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of genetic events are highlighted?",{"text":117,"@type":113},"The review emphasizes genetic aberrations, oncogenic fusions, and dysregulated signaling pathways reported across benign and malignant SGN subtypes.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are targeted therapies still challenging to apply clinically?",{"text":121,"@type":113},"Although molecular findings suggest potential targets, current therapeutic data are limited and many clinical uses are extrapolated from other cancers, requiring validation in clinical trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346187,1790714387,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Review SCIENCE PROGRESS  \nGenetic alterations and targeted therapies in salivary gland neoplasms  \nSharwani Kota 1  and Richard V Smith2  \nScience Progress 2026, Vol. 109(3) 1–16 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/00368504261430040](DOI: 10.1177/00368504261430040)[ ](DOI: 10.1177/00368504261430040)[journals.sagepub.com/home/sci](journals.sagepub.com/home/sci)  \nAbstract  \nSalivary gland neoplasms (SGNs) represent a diverse group of benign and malignant tumors characterized by distinct genetic abnormalities that contribute to their pathogenesis and variable clinical behavior. This review synthesizes current evidence on the molecular alterations underlying SGNs and highlights emerging therapeutic targets with translational potential. A comprehensive literature search was conducted across PubMed, Google Scholar, Cochrane, and SCOPUS for studies published between 1990 and 2025, focusing on genetic aberrations, oncogenic fusions, and targeted treatment strategies. Data reveal that small molecule inhibitors and other targeted agents may offer promising alternatives to conventional chemotherapy. For instance, pleomorphic adenomas often have PLAG1 overexpression and FGFR1 fusions, activating the IGF and WNT signaling pathways; linsitinib, a dual IGF1Rand tyrosine kinase inhibitor, has demonstrated antitumor activity in other malignancies and may hold potential in this context. Similarly, alterations in EGFR, HER2, and PI3K pathways across multiple salivary tumor subtypes highlight opportunities for small molecular inhibitor therapy. However, current data remain limited, and therapeutic applications are largely extrapolated from other cancers. Further research is needed to validate these ﬁndingsin clinical trials. Overall, integrating molecular diagnostics with pathway-speciﬁctargeted therapies may enhance outcomes and expand treatment options for patients with SGNs.  \nKeywords  \nSalivary gland neoplasms, genetic aberrations, small molecule inhibitors, therapeutic targets  \n1 Robert Wood Johnson Medical School, Piscataway, NJ, USA  \n2Department of Otorhinolaryngology-Head and Neck Surgery, Monteﬁore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA  \nCorresponding author:  \nRichard V Smith, Department of Otorhinolaryngology-Head and Neck Surgery, Monteﬁore Health System, Albert Einstein College of Medicine, 3400 Bainbridge Ave, Bronx, NY 10467, USA.  \nEmail: rsmith@monteﬁ[ore.org](ore.org)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms  \nof the Creative Commons Attribution-NonCommercial 4.0 License ([https://](https://)[ ](https://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access page ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \nIntroduction  \nSalivary gland neoplasms (SGNs) are rare tumors with more than 30 histologically and genetically distinct subtypes.1–3 Approximately 5 per 100,000 individuals are diagnosed with SGNs annually, the majority of which are benign and arise from either major or minor salivary glands, each with differing malignant potential.4–6 Major histologic subtypes of benign salivary gland tumors include pleomorphic adenoma (60–70%), papillary cystadenoma, myoepithelioma, and Warthin’s tumor.3 Major types of malignant salivary gland neoplasms include mucoepidermoid carcinoma (MEC; 30–35%), adenoid cystic carcinoma (ACC), acinic cell carcinoma (ACiCC), and salivary duct carcinoma (SDC) .2 Collectively, these tumors exhibit marked heterogeneity in clinical behavior, prognosis, and therapeutic responsiveness.  \nAlthough surgery with or without adjuvant radiotherap","cbCaimyqu4LMFDUT","https://ap.wps.com/l/cbCaimyqu4LMFDUT","pdf",526102,16,"English","# Introduction\n# Methods\n## Search strategy","[{\"question\":\"What does the review focus on regarding salivary gland neoplasms?\",\"answer\":\"It focuses on genetic and molecular alterations in SGNs and how they relate to diagnosis, prognosis, and targeted therapy development.\"},{\"question\":\"Which types of genetic events are highlighted?\",\"answer\":\"The review emphasizes genetic aberrations, oncogenic fusions, and dysregulated signaling pathways reported across benign and malignant SGN subtypes.\"},{\"question\":\"Why are targeted therapies still challenging to apply clinically?\",\"answer\":\"Although molecular findings suggest potential targets, current therapeutic data are limited and many clinical uses are extrapolated from other cancers, requiring validation in clinical trials.\"}]","Genetic alterations and targeted therapies in salivary gland neoplasms | PDF",1790060418,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a37418218c44e58bd7c1c8e6b6bde86a.webp",983,1415,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bccda2fa0458b6ee2fe403a6f1fba84.webp",982,1414,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2952e297917ee12742aff89c2e00efc5.webp",981,1412,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ed0ad16288dbe6ec00ce29949a177fe.webp",980,1411]